for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Grifols SA

GRLS.MC

Latest Trade

23.66EUR

Change

-0.20(-0.84%)

Volume

836,160

Today's Range

23.66

 - 

24.01

52 Week Range

21.41

 - 

34.31

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Latest Developments

Grifols Executes JV To Develop 20 Plasma Collection Centers In Egypt

Nov 24 (Reuters) - Grifols SA <GRLS.MC>::SAYS HAS EXECUTED BINDING MASTER JOINT VENTURE AGREEMENT WITH EGYPTIAN BASED NATIONAL SERVICE PROJECTS ORGANIZATION.JV WILL BE OWNED BY GRIFOLS AND NSPO ON A 49%-51% BASIS RESPECTIVELY.JV WILL JOIN BOTH COMPANIES INDUSTRIAL EXPERTISE AND FINANCIAL EFFORTS FOR THE DEVELOPMENT, CONSTRUCTION AND OPERATION OF 20 PLASMA COLLECTION CENTERS THROUGHOUT EGYPT.TOTAL EXPECTED CAPITAL EXPENDITURE FOR PROJECT IS ESTIMATED TO BE $300 MILLION AND IS TO BE DISBURSED BY SHAREHOLDERS ACCORDING TO THEIR PERCENTAGE OWNERSHIP.INITIAL AGGREGATE INVESTMENT OF $20 MILLION WILL BE MADE BY GRIFOLS AND NSPO UPON THE INCORPORATION OF THE JV.WILL SECURE PROCESSING OF PLASMA COLLECTED IN EGYPT INTO PLASMA-DERIVED PRODUCTS TO SERVE EGYPTIAN NATIONAL NEEDS WHILST MANUFACTURING FACILITIES ARE PENDING TO BE FINALIZED AND FULLY UP AND RUNNING.NON-BINDING TERM SHEET EXECUTED BY AND BETWEEN GRIFOLS AND PUBLIC INVESTMENT FUND OF SAUDI ARABIA HAS BEEN TERMINATED BY MUTUAL AGREEMENT.

Grifols Buys 49% In MedKeeper, For USD 60.2 Mln

Nov 9 (Reuters) - Grifols SA <GRLS.MC>::IT HAS ACQUIRED, THROUGH ITS UNIT GRIFOLS SHARED SERVICES NORTH AMERICA INC., A 49% INTEREST IN THE COMPANY GOETECH LLC, DOING BUSINESS AS MEDKEEPER, FOR THE AMOUNT OF USD 60.2 MILLION.IN JANUARY 2018 GRIFOLS ALREADY ACQUIRED A 51% INTEREST IN MEDKEEPER.

Grifols Expects To Increase Its Plasma Supply By 30% In 2021

Nov 5 (Reuters) - Grifols SA <GRLS.MC>::WITH IMPLEMENTATION OF ITS EXPANSION PLAN, THE COMPANY EXPECTS TO INCREASE ITS PLASMA SUPPLY BY ROUGHLY 30% IN 2021.

Grifols 9-Month Net Profit Up 14.7% YoY

Nov 5 (Reuters) - GRIFOLS SA <GRLS.MC>::9-MONTH NET SALES 4.03 BILLION EUROS VERSUS 3.74 BILLION EUROS YEAR AGO.9-MONTH REPORTED EBITDA 983.6 MILLION EUROS VERSUS 1.07 BILLION EUROS YEAR AGO.9-MONTH RESEARCH AND DEVELOPMENT NET INVESTMENT 247.3 MILLION EUROS VERSUS 244.6 MILLION EUROS YEAR AGO.9-MONTH NET PROFIT 485.7 MILLION EUROS VERSUS 423.4 MILLION EUROS YEAR AGO.9-MONTH ADJUSTED NET PROFIT 567.3 MILLION EUROS VERSUS 486.2 MILLION EUROS YEAR AGO.

Grifols Expects Full Recovery Of Its Plasma Volumes By 2021

Sept 14 (Reuters) - Grifols SA <GRLS.MC>::EXPECTS FULL RECOVERY OF ITS PLASMA VOLUMES BY 2021.THROUGH ITS STRATEGIC EXPANSION PLAN, GRIFOLS ESTIMATES TO INCREASE ITS PLASMA VOLUMES BY APPROXIMATELY 30% IN 2021.SAYS FORESEES STRONG UNDERLYING DEMAND FOR ITS PLASMA-DERIVED THERAPIES, ESPECIALLY IMMUNOGLOBULINS INCLUDING HYPERIMMUNES AND ALBUMIN.

Grifols Gets Agreement To Buy Remaining Shares Of Alkahest, about 55%, for $146 Mln

Sept 7 (Reuters) - Grifols SA <GRLS.MC>::SAYS EXECUTED AGREEMENT WITH REMAINING SHAREHOLDERS IN ALKAHEST INC. TO BUY REMAINING SHARES OF ALKAHEST (ABOUT 55%).SAYS DEAL FOR A TOTAL OF $146 MILLION, ON A DEBT FREE BASIS.CLOSING OF THE TRANSACTION IS SUBJECT TO APPROVAL BY THE RELEVANT ANTITRUST AUTHORITIES, AND IS EXPECTED TO TAKE PLACE IN EARLY 2021.SAYS NO ADDITIONAL FINANCING WILL BE REQUIRED.ALREADY ACQUIRED STAKE OF ABOUT 45% OF ALKAHEST IN MARCH 2015, WITH THIS TRANSACTION GAINS TOTAL CONTROL.

Grifols H1 Net Profit Down 23.9% YoY

July 30 (Reuters) - Grifols SA <GRLS.MC>:H1 NET SALES 2.68 BILLION EUROS VERSUS 2.42 BILLION EUROS YEAR AGO.H1 NET PROFIT 218.2 MILLION EUROS VERSUS 286.9 MILLION EUROS YEAR AGO.H1 RESEARCH AND DEVELOPMENT NET INVESTMENT 166.8 MILLION EUROS VERSUS 167.7 MILLION EUROS YEAR AGO.H1 REPORTED EBITDA 579.9 MILLION EUROS VERSUS 697 MILLION EUROS YEAR AGO.

Grifols Says Negative Net Impact Of 185 Mln Euros Due To COVID-19

July 30 (Reuters) - Grifols SA <GRLS.MC>::HAS ESTIMATED A TEMPORARY IMPACT DERIVED FROM COVID-19.RECOGNISED AN ESTIMATED IMPACT OF 205 MILLION EUROS IN THE 2020 FISCAL YEAR TO ADJUST ITS INVENTORY VALUE MAINLY DUE TO COVID-19, BASED ON INFORMATION AVAILABLE TO DATE.CONTAINMENT PLAN OF OPERATING EXPENSES IS EXPECTED TO YIELD A POSITIVE IMPACT OF 100 MILLION EUROS ON THE 2020 CONSOLIDATED PROFIT-AND-LOSS ACCOUNT.AS OF JUNE 30, 2020, THE PROFIT AND LOSS STATEMENT INCLUDES A NEGATIVE NET IMPACT OF 185 MILLION EUROS MAINLY DUE TO COVID-19.ESTIMATES THAT PLASMA COLLECTION EXPECT TO HAVE A NET IMPACT OF 10% IN TERMS OF PLASMA AVAILABILITY IN 2020 COMPARED TO 2019.COMPANY IS EQUIPPED TO RESPOND TO THE DEMANDS OF THE CURRENT CONTEXT AND REMAINS COMMITTED TO ITS LONG-TERM GROWTH STRATEGY.

Grifols Delivers First Manufactured Batches Of Anti-Sars-Cov-2 Hyperimmune Globulin For Clinical Trial

July 28 (Reuters) - Grifols SA <GRLS.MC>::SAYS DELIVERS FIRST MANUFACTURED BATCHES OF ITS ANTI-SARS-COV-2 HYPERIMMUNE GLOBULIN FOR CLINICAL TRIAL.SAYS THERAPY, WHICH PROVIDES PASSIVE IMMUNITY AND COULD BE USED FOR BOTH PREVENTION AND TREATMENT, WILL UNDERGO CLINICAL TRIALS THIS SUMMER.SAYS MEDICINE TARGETS SARS-COV-2 BY PROVIDING PASSIVE IMMUNITY TO INFECTED PATIENTS AND BOOSTING IMMUNE SYSTEM ABILITY TO FIGHT DISEASE.

Grifols Buys 10% Stake In Bloodbuy, Cloud-Based Marketplace For Blood Products

July 23 (Reuters) - Grifols SA <GRLS.MC>::BUYS 10% STAKE IN BLOODBUY, CLOUD-BASED MARKETPLACE FOR BLOOD PRODUCTS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up